Yuesai Biotechnology has completed a strategic A+ round financing of nearly 100 million yuan to accelerate the development of innovative cell therapy drugs targeting neurological disorders.

Target Company Overview

Yuesai Biotechnology has successfully completed a strategic A+ round financing amounting to nearly 100 million yuan, led by the Shanghai Guotou Pioneer Biomedicine Industrial Fund and the Pudong Venture Capital Group's Leading Zone Fund. The funds will be utilized to accelerate the company's pipeline development and clinical trial progress, further advancing the large-scale development and industrialization of innovative cell therapy drugs. Since its establishment in 2021, Yuesai Biotechnology has been dedicated to developing the next generation of cell therapy drugs based on human pluripotent stem cell technology, establishing an innovative technology platform for the independent research and development of pluripotent stem cell-derived drugs. This platform covers the entire process from research and development to clinical trial approval, with multiple research achievements published in top international academic journals such as Cell Stem Cell.

The company's research pipeline addresses various neurological disorders, including Parkinson's disease and epilepsy. Notably, their product UX-DA001 has become the first autologous cell therapy project for Parkinson's disease to secure dual regulatory approval for clinical trials in both China and the United States, and it has received Fast Track designation from the FDA. Currently, UX-DA001 is undergoing Phase I clinical trials at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, where several patient cell transplants have been completed with favorable safety and tolerability outcomes, as well as promising initial efficacy signals, laying a solid foundation for subsequent clinical development.

Industry Overview in China

The biotechnology sector in China has been experiencing rapid growth and development, driven by significant investments and advancements in technology. The Chinese government has prioritized the biotech industry as a strategic focus, implementing